Leonard John M.
President and CEO at NTLA; Director at IQV; Director at CHIMERIX INC, and 1 more
- Sold, on record
- $60.9M
- Dollars the filings state
- Form 4 sales
- 28
- Latest Aug 21, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- NTLAIntellia Therapeutics, Inc.President and CEO
- IQVIQVIA HOLDINGS INC.Director
- CHIMERIX INCDirector
- ABBVAbbVie Inc.SVP, Chief Scientific Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- NTLA832,934 shares
- ABBV74,649 shares
- IQV20,200 shares
- CHIMERIX INC5,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale NTLAUnusualSep 1, 2021 2021
Sold 121,372 shares at $160.83 ($19.5M)
Leonard John M, President and CEO
Sold 14.4% of holdings ($135M position)719,305 shares left5.4x usual sizeFiling
- 2 Form 4 sale NTLAPlan not statedJan 1, 2022 +122 days
Sold 2,493 shares at $112.26 ($280k)
Leonard John M, President and CEO
Sold 0.3% of holdings ($81.6M position)724,660 shares left0.1x usual sizeFiling
- 3 Form 4 sale NTLAPlan not statedJan 4, 2023 +368 days
Sold 6,673 shares at $37.21 ($248k)
Leonard John M, President and CEO
Sold 0.9% of holdings ($28.8M position)766,825 shares left0.2x usual sizeFiling
- 4 Form 4 sale NTLANo planJan 3, 2024 +364 days
Sold 19,223 shares at $29.46 ($566k)
Leonard John M, President and CEO
No 10b5-1 planSold 2.2% of holdings ($25.5M position)846,486 shares leftFiling
- 5 Form 4 sale NTLANo planJan 3, 2025 +366 days
Sold 26,807 shares at $12.18 ($327k)
Leonard John M, President and CEO
No 10b5-1 planSold 2.8% of holdings ($11.8M position)941,115 shares leftFiling
- 6 Form 4 sale NTLARoutineDec 11, 2025 +342 days
Sold 88,146 shares at $9.49 ($836k)
Leonard John M, President and CEO
10b5-1 planSold 7.8% of holdings ($10.7M position)1M shares leftFiling
- 7 Form 4 sale NTLANo planJan 5, 2026 +25 days
Sold 34,146 shares at $9.21 ($314k)
Leonard John M, President and CEO
No 10b5-1 planSold 3.3% of holdings ($9.6M position)1M shares leftFiling
- 8 Form 4 sale NTLARoutineAug 21, 2026 +228 days
Sold 22,675 shares at $12.65 ($287k)
Leonard John M, President and CEO
10b5-1 planSold 1.9% of holdings ($14.8M position)1.1M shares left0.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (28)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Aug 24, 2026 | NTLA | President and CEO | Form 4 sale | 22,675 | $287k | 1.9% | Routine | SEC |
| Jan 5, 2026 | Jan 7, 2026 | NTLA | President and CEO | Form 4 sale | 34,146 | $314k | 3.3% | No plan | SEC |
| Dec 11, 2025 | Dec 12, 2025 | NTLA | President and CEO | Form 4 sale | 88,146 | $836k | 7.8% | Routine | SEC |
| Jan 3, 2025 | Jan 7, 2025 | NTLA | President and CEO | Form 4 sale | 26,807 | $327k | 2.8% | No plan | SEC |
| Jan 3, 2024 | Jan 5, 2024 | NTLA | President and CEO | Form 4 sale | 19,223 | $566k | 2.2% | No plan | SEC |
| Jan 4, 2023 | Jan 6, 2023 | NTLA | President and CEO | Form 4 sale | 6,673 | $248k | 0.9% | Plan not stated | SEC |
| Jan 1, 2022 | Mar 4, 2022 | NTLA | President and CEO | Form 4 sale | 2,493 | $280k | 0.3% | Plan not stated | SEC |
| Sep 1, 2021 | Sep 1, 2021 | NTLA | President and CEO | Form 4 sale | 121,372 | $19.5M | 14.4% | Unusual | SEC |
| Aug 23, 2021 | Aug 25, 2021 | NTLA | President and CEO | Form 4 sale | 27,139 | $4.1M | 3.6% | Plan not stated | SEC |
| Aug 19, 2021 | Aug 20, 2021 | NTLA | President and CEO | Form 4 sale | 22,682 | $3.4M | 3.1% | Plan not stated | SEC |
| Apr 1, 2021 | Apr 2, 2021 | NTLA | President and CEO | Form 4 sale | 38,209 | $3.2M | 5.2% | Plan not stated | SEC |
| Feb 9, 2021 | Feb 9, 2021 | NTLA | President and CEO | Form 4 sale | 50,985 | $3.7M | 7.2% | Unusual | SEC |
| Feb 3, 2021 | Feb 3, 2021 | NTLA | President and CEO | Form 4 sale | 177,745 | $12M | 22.4% | Unusual | SEC |
| Jan 5, 2021 | Jan 5, 2021 | NTLA | President and CEO | Form 4 sale | 6,239 | $349k | 1.3% | Plan not stated | SEC |
| Nov 27, 2020 | Nov 27, 2020 | NTLA | President and CEO | Form 4 sale | 35,000 | $1.4M | 7.0% | Unusual | SEC |
| Nov 25, 2020 | Nov 25, 2020 | NTLA | President and CEO | Form 4 sale | 50,000 | $1.8M | 9.7% | Unusual | SEC |
| Nov 16, 2020 | Nov 18, 2020 | NTLA | President and CEO | Form 4 sale | 20,000 | $680k | 4.1% | Unusual | SEC |
| Nov 4, 2020 | Nov 6, 2020 | NTLA | President and CEO | Form 4 sale | 50,000 | $1.3M | 9.7% | Unusual | SEC |
| Oct 7, 2020 | Oct 9, 2020 | NTLA | President and CEO | Form 4 sale | 5,000 | $109k | 1.1% | Plan not stated | SEC |
| Sep 1, 2020 | Sep 3, 2020 | NTLA | President and CEO | Form 4 sale | 5,000 | $109k | 1.1% | Plan not stated | SEC |
| Aug 6, 2020 | Aug 7, 2020 | NTLA | President and CEO | Form 4 sale | 5,000 | $109k | 1.1% | Plan not stated | SEC |
| Jul 1, 2020 | Jul 2, 2020 | NTLA | President and CEO | Form 4 sale | 5,000 | $109k | 1.1% | Plan not stated | SEC |
| Jun 3, 2020 | Jun 5, 2020 | NTLA | President and CEO | Form 4 sale | 5,000 | $109k | 1.1% | Plan not stated | SEC |
| Dec 20, 2019 | Dec 26, 2019 | IQV | Director | Form 4 sale | 20,200 | $3.1M | 71.0% | Unusual | SEC |
| May 14, 2018 | May 15, 2018 | NTLA | President and CEO | Form 4 sale | 8,400 | $202k | 100.0% | Unusual | SEC |
| Sep 15, 2016 | Sep 16, 2016 | CHIMERIX INC | Director | Form 4 sale | 5,000 | $25k | 100.0% | Unusual | SEC |
| Mar 15, 2013 | Mar 19, 2013 | ABBV | SVP, Chief Scientific Officer | Form 4 sale | 46,700 | $1.8M | 30.3% | Unusual | SEC |
| Mar 8, 2013 | Mar 12, 2013 | ABBV | SVP, Chief Scientific Officer | Form 4 sale | 27,949 | $1M | 20.7% | Plan not stated | SEC |